menu
    • menu
    [{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Adrenomed

    Menu

    Adrenomed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AdrenoMed Receives FDA Fast Track Designation for Enibarcimab in Septic Shock Treatment

                            Details : HAM8101 (enibarcimab) is an adrenomedullin receptor binder, intravenously administered, antibody, which is currently being evaluated for the treatment of septic shock.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 10, 2024

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Sh...

                            Details : EMA supports Adrenomed’s strategy to continue development of Adrecizumab based on the completed Phase II trial AdrenOSS-2, which demonstrated favorable safety and tolerability and a positive survival trend.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 02, 2021

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targeting Endothelial Barrier Function in Critically Ill Covid-19 Patients: Adrecizumab Shows Beneficial Effec...

                            Details : Treatment with Adrecizumab showed an encouraging outcome in this limited data set, seven out of eight patients survived the observation period. Adrecizumab targets Adrenomedullin to restore endothelial barrier function and impaired vascular integrity.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 24, 2020

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Adrenomed

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock

                            Details : The study achieved its primary endpoint: Adrecizumab demonstrated a favorable safety profile and was well tolerated.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 21, 2020

                            Lead Product(s) : Adrecizumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth